FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cresco Labs's Free Cash Flow for the
three
months ended in Mar. 2026 was €-13.5 Mil. Cresco Labs's Revenue for the
three
months ended in Mar. 2026 was €130.9 Mil. Therefore, Cresco Labs's FCF Margin % for the quarter that ended in Mar. 2026 was -10.28%.
The historical rank and industry rank for Cresco Labs's FCF Margin % or its related term are showing as below:
FRA:6CQ'
s FCF Margin % Range Over the Past 10 Years
Min: -94.38 Med: -8 Max: 15.05
Current: -0.7
During the past 13 years, the highest FCF Margin % of Cresco Labs was 15.05%. The lowest was -94.38%. And the median was -8.00%.
FRA:6CQ's FCF Margin % is ranked worse than 59.39% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs FRA:6CQ: -0.70
Cresco Labs FCF Margin % Related Terms
Cresco Labs FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cresco Labs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cresco Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (FRA:6CQ) has a FCF Margin % of -10.28% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cresco Labs and its competitors. According to the industry distribution chart, Cresco Labs ranks #569 out of 958 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is Cresco Labs' FCF Margin % too high?
Cresco Labs' current FCF Margin % is -10.28%. Based on the distribution chart, Cresco Labs ranks #569 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cresco Labs has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #569 out of 958 companies for FCF Margin %. This places Cresco Labs in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current FCF Margin % is -10.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.88, compared to a current price of €0.69 — trading 21.1% below its estimated fair value. The current FCF Margin % is -10.28%. Cresco Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current FCF Margin % is -10.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (FRA:6CQ) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of €0.69 is trading 21.1% below its estimated GF Value™ of €0.88.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for FRA:6CQ:
FCF Margin %: -10.28%
GF Value™: €0.88 vs. price of €0.69 (21.1% below fair value)
No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
66GF Score
Get the complete analysis for FRA:6CQ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6CQ has been successfully added to your 
